ONCT Stock Price, Oncternal Therapeutics Quote, Chart

Market Summary

USD8.95+0.13

Delayed

1.47%

ONCT Alerts

1 major insider buys recently.

ONCT Stock Price

View Fullscreen

ONCT RSI Chart

ONCT Valuation

Market Cap

26.5M

Price/Earnings (Trailing)

-0.73

Price/Sales (Trailing)

23.01

EV/EBITDA

-0.49

Price/Free Cashflow

-0.93

ONCT Price/Sales (Trailing)

ONCT Profitability

EBT Margin

-3424.07%

Return on Equity

-158.68%

Return on Assets

-124.84%

Free Cashflow Yield

-108.09%

ONCT Fundamentals

ONCT Revenue

Revenue (TTM)

1.2M

Rev. Growth (Yr)

180.3%

Rev. Growth (Qtr)

91.58%

ONCT Earnings

Earnings (TTM)

-36.4M

Earnings Growth (Yr)

26.98%

Earnings Growth (Qtr)

8.47%

Breaking Down ONCT Revenue

Last 7 days

9.4%

Last 90 days

6.3%

Trailing 12 Months

2879.4%

How does ONCT drawdown profile look like?

ONCT Financial Health

Current Ratio

4.66

ONCT Investor Care

Buy Backs (1Y)

94.96%

Diluted EPS (TTM)

-16.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.2M	0	0	0
2023	947.0K	862.0K	659.0K	785.0K
2022	4.3M	3.6M	1.9M	1.5M
2021	3.5M	3.8M	5.3M	4.3M
2020	2.5M	2.5M	2.5M	3.4M
2019	2.8M	1.9M	2.2M	2.4M
2018	0	5.4M	3.7M	4.2M
2012	5.5M	0	0	0
2011	45.5M	34.3M	23.0M	11.7M
2010	0	28.7M	42.8M	56.8M
2009	0	0	0	14.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Oncternal Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	wills robert james	bought	27,654	8.9613	3,086	-
Mar 28, 2024	wills robert james	bought	58,602	8.4759	6,914	-
Feb 23, 2024	hale david f	bought	6,454	9.04	714	-
Feb 23, 2024	hale david f	bought	2,404	9.04	266	-
Feb 23, 2024	wills robert james	sold	-8,859	9.04	-980	-
Jan 03, 2024	breitmeyer james b	sold (taxes)	-25,278	0.4961	-50,955	chief executive officer
Jan 03, 2024	vincent richard g	sold (taxes)	-4,399	0.4961	-8,868	chief financial officer
Jan 03, 2024	krishnan rajesh	sold (taxes)	-5,872	0.4961	-11,838	chief technical officer
Jan 03, 2024	breitmeyer james b	sold (taxes)	-2,225	0.4961	-4,485	chief executive officer
Jan 03, 2024	yazji salim	sold (taxes)	-9,794	0.4961	-19,742	chief medical officer

Which funds bought or sold ONCT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-1,102,380	-	-%
May 15, 2024	Beta Wealth Group, Inc.	sold off	-100	-17,158	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-2,660	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	5,976	5,976	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	sold off	-100	-44,826	-	-%
May 15, 2024	ADAR1 Capital Management, LLC	new	-	22,248	22,248	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	sold off	-100	-161	-	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	new	-	135	135	-%
May 15, 2024	IPG Investment Advisors LLC	sold off	-100	-12,504	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-31,508	-	-%

Are Funds Buying or Selling ONCT?

Are funds buying ONCT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ONCT

No. of Funds

ONCT Alerts

1 major insider buys recently.

Unveiling Oncternal Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	4.85%	2,860,906	SC 13G/A
Jul 08, 2022	blackrock inc.	2.0%	1,005,532	SC 13G
Feb 04, 2022	blackrock inc.	6.5%	3,197,538	SC 13G
Feb 16, 2021	armistice capital, llc	3.0%	1,280,930	SC 13G/A
Feb 16, 2021	cvi investments, inc.	-	0	SC 13G/A
Dec 18, 2020	cvi investments, inc.	-	2,500,000	SC 13G
Dec 18, 2020	hyde joseph r iii	2.99%	1,468,142	SC 13D/A
Jul 23, 2020	shanghai pharmaceuticals (hk) investment ltd	7.7%	1,573,975	SC 13D/A
May 29, 2020	armistice capital, llc	9.1%	1,576,471	SC 13G
Feb 14, 2020	perceptive advisors llc	0%	0	SC 13G/A

Recent SEC filings of Oncternal Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 01, 2024	EFFECT	EFFECT
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 10, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 08, 2024	S-3	S-3
Mar 07, 2024	10-K	Annual Report

Peers (Alternatives to Oncternal Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Oncternal Therapeutics Inc News

Latest updates

Oncternal Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	91.6%	569,000	297,000	179,000	106,000	203,000	171,000	382,000	191,000	746,000	556,000	2,128,000	883,000	748,000	1,588,500	585,000	623,000	578,000	736,500	544,000	674,000	470,000
Operating Expenses	-5.9%	9,348,000	9,933,000	10,569,000	9,651,000	12,346,000	12,086,000	11,707,000	11,986,000	10,658,000	8,636,000	11,765,000	8,573,000	6,707,000	4,449,500	4,980,000	6,158,000	5,329,000	4,917,500	5,493,000	22,294,000	2,828,000
S&GA Expenses	-100.0%	-	3,263,000	3,094,000	3,074,000	3,315,000	3,288,000	3,265,000	3,225,000	3,679,000	2,618,000	2,802,000	3,381,000	2,794,000	1,463,500	1,933,000	2,343,000	2,633,000	2,349,500	2,385,000	1,619,000	932,000
EBITDA Margin	31.8%	-34.20	-50.15	-59.73	-45.67	-41.57	-26.42	-20.99	-10.87	-9.13	-9.12	-7.36	-10.35	-11.11	-	-	-	-	-	-	-	-
EBT Margin	31.8%	-34.24	-50.21	-59.80	-45.72	-41.62	-26.45	-21.02	-10.88	-9.14	-9.13	-7.37	-10.36	-11.12	-	-	-	-	-	-	-	-
Net Income	8.5%	-8,388,000	-9,164,000	-9,862,000	-8,966,000	-11,487,000	-11,400,000	-11,125,000	-11,741,000	-9,904,000	-8,073,000	-9,630,000	-7,682,000	-5,948,000	-2,557,000	-4,395,000	-5,535,000	-4,738,000	-4,156,000	-4,892,000	-22,846,000	-2,294,000
Net Income Margin	37.2%	-31.61	-50.29	-63.30	-49.86	-48.31	-29.64	-21.78	-10.87	-8.18	-7.26	-4.83	-5.41	-5.20	-	-	-	-	-	-	-	-
Free Cashflow	-15.9%	-7,438,000	-6,419,000	-5,513,000	-9,263,000	-10,969,000	-9,002,000	-11,966,000	-7,130,000	-8,606,000	-6,616,000	-6,380,000	-7,608,000	-5,985,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-20.7%	29.00	37.00	43.00	51.00	58.00	69.00	76.00	82.00	85.00	94.00	100	108	114	119	24.00	19.00	18.00	22.00	25.00	31.00	23.00
Current Assets	-21.0%	29.00	36.00	42.00	50.00	58.00	67.00	75.00	81.00	85.00	93.00	100	108	113	118	23.00	18.00	17.00	21.00	24.00	30.00	23.00
Cash Equivalents	-4.5%	6.00	7.00	15.00	16.00	11.00	37.00	71.00	79.00	82.00	91.00	97.00	104	111	117	21.00	17.00	16.00	20.00	23.00	29.00	21.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00
Liabilities	-6.9%	6.00	7.00	6.00	6.00	-	8.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	17.7%	6.00	5.00	5.00	5.00	5.00	8.00	8.00	8.00	5.00	5.00	6.00	6.00	6.00	6.00	8.00	9.00	7.00	7.00	7.00	8.00	2.00
Shareholder's Equity	-23.7%	23.00	30.00	37.00	45.00	52.00	61.00	69.00	74.00	80.00	88.00	94.00	103	108	113	16.00	10.00	10.00	14.00	18.00	23.00	21.00
Retained Earnings	-4.2%	-206	-197	-188	-178	-169	-158	-146	-135	-124	-114	-106	-96.43	-88.70	-82.80	-80.20	-75.80	-70.31	-65.57	-61.42	-56.52	-605
Additional Paid-In Capital	0.6%	229	228	226	224	222	219	215	210	204	202	200	199	197	196	96.00	85.00	81.00	80.00	80.00	79.00	627
Shares Outstanding	0.4%	3.00	3.00	59.00	59.00	59.00	-	51.00	50.00	49.00	49.00	49.00	49.00	49.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	19.00	-	-	-	0.00	-	-	-	212	-	-	-	27.00	-	-	-	62.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-15.9%	-7,438	-6,419	-5,513	-9,263	-10,969	-9,002	-11,966	-7,130	-8,606	-6,616	-6,380	-7,608	-5,985	-3,911	-5,327	-4,221	-4,036	-3,045	-3,829	-6,239	-3,633
Share Based Compensation	-38.7%	1,360	2,218	1,717	1,680	1,885	1,802	1,974	1,677	1,978	1,713	1,488	1,836	838	407	407	343	399	315	90.00	63.00	39.00
Cashflow From Investing	499.6%	7,224	-1,808	4,655	13,852	-16,048	-26,498	-	-	-	-	-	-	-	-	-	-	-	-	-1,604	17,820	-79.00
Cashflow From Financing	-8600.0%	-87.00	-1.00	-49.00	-1.00	1,119	2,014	3,694	3,871	-	1.00	97.00	60.00	459	99,389	9,969	4,819	4.00	-	13.00	-	2.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ONCT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Grant revenue	$ 569	$ 203
Operating expenses:
Research and development	6,059	9,031
General and administrative	3,289	3,315
Total operating expenses	9,348	12,346
Loss from operations	(8,779)	(12,143)
Interest income	391	656
Net loss	(8,388)	(11,487)
Comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities, net	(11)	2
Comprehensive loss	$ (8,399)	$ (11,485)
Net loss per share, basic	$ (2.83)	$ (3.93)
Net loss per share, diluted	$ (2.83)	$ (3.93)
Weighted-average shares outstanding, basic	2,959	2,926
Weighted-average shares outstanding, diluted	2,959	2,926

ONCT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 6,396	$ 6,697
Short-term investments	20,631	27,558
Prepaid and other	1,477	1,804
Total current assets	28,504	36,059
Right-of-use asset	225	258
Other assets	412	412
Total assets	29,141	36,729
Current liabilities:
Accounts payable	1,462	1,148
Accrued liabilities	4,475	3,877
Lease, current	179	173
Total current liabilities	6,116	5,198
Deferred compensation	0	1,334
Lease, net of current	99	145
Total liabilities	6,215	6,677
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized shares - 5,000 at March 31, 2024 and December 31, 2023; issued shares - none	0	0
Common stock, $0.001 par value; authorized shares - 120,000; issued and outstanding shares - 2,960 and 2,948 at March 31, 2024 and December 31, 2023, respectively	3	3
Additional paid-in capital	229,098	227,825
Accumulated comprehensive income (loss)	(8)	3
Accumulated deficit	(206,167)	(197,779)
Total stockholders’ equity	22,926	30,052
Total liabilities and stockholders’ equity	$ 29,141	$ 36,729

About Oncternal Therapeutics Inc

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

CEO	Dr. James B. Breitmeyer M.D., Ph.D.
WEBSITE	oncternal.com
INDUSTRY	Biotechnology
EMPLOYEES	30

Oncternal Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Oncternal Therapeutics Inc? What does ONCT stand for in stocks?

ONCT is the stock ticker symbol of Oncternal Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Oncternal Therapeutics Inc (ONCT)?

As of Fri May 17 2024, market cap of Oncternal Therapeutics Inc is 26.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ONCT stock?

You can check ONCT's fair value in chart for subscribers.

What is the fair value of ONCT stock?

You can check ONCT's fair value in chart for subscribers. The fair value of Oncternal Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Oncternal Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ONCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Oncternal Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ONCT is over valued or under valued. Whether Oncternal Therapeutics Inc is cheap or expensive depends on the assumptions which impact Oncternal Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ONCT.

What is Oncternal Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ONCT's PE ratio (Price to Earnings) is -0.73 and Price to Sales (PS) ratio is 23.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ONCT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Oncternal Therapeutics Inc's stock?

In the past 10 years, Oncternal Therapeutics Inc has provided -0.04 (multiply by 100 for percentage) rate of return.